Mode
Text Size
Log in / Sign up
N/A Completed N=41 Randomized Basic Science

Developing Strategies for Effective Debridement in Patients for Venous Leg Ulcers

Source: ClinicalTrials.gov NCT03796793 ↗
Enrolled (actual)
41
Serious AEs
2.4%
Results posted
May 2026
Primary outcomePrimary: Change in the Genetic Profile After Debridement in the Intervention Group. — 1031 Number of Differentially Expressed Genes

Summary

The goal of this project is to use genomic profiling, candidate genes and proteins to develop guided surgical debridement to improve healing in chronic non-healing venous leg ulcers (VLUs) and to test the efficacy of this approach.

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in the Genetic Profile After Debridement in the Intervention Group.
1031
SECONDARY
Percent Rate of Healing Versus Non-healing Wounds Within Each Treatment Group
62.5; 21.4; 37.5; 78.6

Eligibility Criteria

Inclusion Criteria

  • >18 years of age
  • Conformation of venous disease by non-invasive venous studies with either Doppler-confirmed venous reflux, or having ≥ 2 clinical characteristics of venous insufficiency (varicose veins, lipodermatosclersosis, venous dermatitis, atrophie blanche, edema)
  • have a venous ulcer between the knee and ankle, at or above the malleolus
  • wound size would be greater than or equal to 5cm2 in area without exposed tendon, muscle or bone
  • wound duration of at least 6 months
  • VLU containing yellow/white slough with or without fibrous/scar tissue and/or non-viable tissue
  • ability of subject to tolerate limb compression bandage

Exclusion Criteria

  • history of diabetes mellitus and a HbA1c > 12% (obtained within past 6 months)
  • Ankle brachial index(ABI) less than 0.80
  • any active cancer other than a nonmelanoma skin cancer; any previous cancer must be in remission for at least 5 years
  • suspicion of malignancy within VLU
  • life expectancy 2x upper limit of normal (obtained within past 6 months)
  • requirement for long-term systemic corticosteroids or immunosuppressive therapy, or history of corticosteroid or immunosuppressive use in the 4 weeks prior to study entry
  • history of immunodeficiency
  • ulcers due to none venous etiology and leg ulcers associated with mixed etiology
  • Untreated osteomyelitis
  • Hepatitis
  • acute deep venous thrombosis
  • allergy to lidocaine and/or epinephrine
  • Subject's inability to successfully tolerate compression therapy that is changed weekly
  • Skin ulcer previously treated within the last 4 weeks with biologic therapies (e.g. cell therapy or growth factors)
  • if currently incarcerated
  • known pregnancy
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03796793). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search